Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » PCR » Qiagen, NeuMoDx Aim to Quickly Build Out Test Menu for High-Volume MDx Systems

Qiagen, NeuMoDx Aim to Quickly Build Out Test Menu for High-Volume MDx Systems

Sep 25, 2018
|
Ben Butkus
Premium

NEW YORK (GenomeWeb) – Qiagen is taking aim at the high-throughput, high-volume molecular diagnostics market through its recently announced partnership and merger agreement with molecular diagnostics developer NeuMoDx.

The deal calls for Qiagen to initially distribute the NeuMoDx N288 and NeuMoDx N96 fully integrated molecular testing platforms in Europe and other ex-US markets, while Ann Arbor, Michigan-based NeuMoDx will continue to market its systems and tests in its home country.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Working Out the Effect

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Increased Genetic Privacy in Florida

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

Attention-Grabbing in Two Ways

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

Nature Papers Describe CRISPR Plant Editing Methods, DNA-PAINT Improvements, More

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
16
Featured Webinar

Exploring Tumor Tissue Architecture and Immune Response with Digital Spatial Profiling

Sponsored by
NanoString

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

Sponsored by
Roche

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

What's Popular?

In PCR

  1. CDC Combined COVID-19/Influenza Test Gets FDA Emergency Use Authorization

  2. Yale, NBA Validating RNA Extraction-Free Saliva Test for Coronavirus

    Premium

  3. Centogene Gets Emergency Use Authorization for PCR-Based Coronavirus Test

  4. T2 Biosystems Preliminary Q2 Revenues Up About 40 Percent; Firm Launches COVID-19 Test

  5. FDA Grants EUAs for PCR Coronavirus Tests, Nasal Swab Self-Collection Kit

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.